Interest in inflammation has risen considerably in the cardiology community as a result of the recent CANTOS trial. The large 10,000 patient trial validated the role of inflammation by demonstrating the efficacy of canakinumab— a monoclonal antibody that targets interleukin-1β— in reducing cardiovascular events in people with heart disease and elevated hs-CRP levels. The positive results ...
Ischaemic heart disease
Imaging studies offer new insights into inflammation in CV disease
By Larry Husten
20 Oct 2017